AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00512980
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00776919
Drug: clindamycin / benzoyl peroxide gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day application to the face
Trial: NCT00776919
Drug: clindamycin gel
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day application to the face
Trial: NCT00776919
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day application to the face
Trial: NCT02371941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02129088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
Trial: NCT00004908
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02672293
Drug: Phoslax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
Trial: NCT00665808
Drug: isophane human insulin
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany
Trial: NCT00862641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02176252
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03091348
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate injection
Trial: NCT00687141
Drug: AZD0328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
Trial: NCT00687141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
Trial: NCT02753439
Drug: Geistlich Bio Oss
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction of Impacted 3rd Molars,
Trial: NCT01233232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose bid
Trial: NCT01233232
Drug: AZD5069 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose bid
Trial: NCT01233232
Drug: AZD5069 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose bid
Trial: NCT02230917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02141737
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
Trial: NCT02141737
Drug: Fentanyl Citrate Injection
RxNorm normalized name: Fentanyl Citrate Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
Trial: NCT01395524
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral tablet once daily
Trial: NCT01395524
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet once daily
Trial: NCT01395524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet intake once daily
Trial: NCT01217307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily during 4 months
Trial: NCT02479308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be matched to Moxifloxacin or ALKS 5461
Trial: NCT01186172
Drug: Ethanol-lock therapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
Trial: NCT01186172
Drug: Antibiotic-lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
Trial: NCT01502267
Drug: High dose IVIG and B cell depleting agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)
Trial: NCT01141569
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01794143
Drug: Sulfonylurea (glimepiride)
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used in accordance with labeling and/or usual practice.
Trial: NCT04001530
Drug: Half Normal Saline 0.45% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization to half normal saline
Trial: NCT04001530
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization to normal saline
Trial: NCT01277770
Drug: Steroid-Free Maintenance Immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 year follow-up of steroid-free maintenance immunosuppression
Trial: NCT01310803
Drug: VALSTAR - Maintenance Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
Trial: NCT02284880
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF - Marketed formulation
Trial: NCT02817425
Drug: SOX Sequential S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
Trial: NCT02817425
Drug: TEGAFOX Sequential S-1.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
Trial: NCT02604160
Drug: LY3113593
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by slow intravenous (IV) infusion.
Trial: NCT02604160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by slow intravenous (IV) infusion.
Trial: NCT01511120
Drug: Tetraspan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
Trial: NCT03771170
Drug: Rheosorbilact®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT03771170
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT00662675
Drug: Pancrease MT 10.5, or MT 21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
Trial: NCT00662675
Drug: Placebo for Pancrease MT 10.5 or MT 21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules with Pancrease MT excipients without the active enzymes
Trial: NCT00552188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dosing, 1 time daily for 24 weeks
Trial: NCT02160899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
Trial: NCT03137264
Drug: Other
RxNorm normalized name: others
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
Trial: NCT01168219
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00490529
Drug: Standard induction chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific, regular medical care treatment as determined by treating oncologist
Trial: NCT00490529
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
Trial: NCT04657666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oromucosal spray
Trial: NCT02468167
Drug: Lauromacrogol
RxNorm normalized name: Lauromacrogol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03300804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo herb formulation
Trial: NCT00087763
Drug: Macugen ™ (pegaptanib sodium injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00229424
Drug: Lafutidine
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of lafutidine by 20mg/day along with famotidine placebo
Trial: NCT01696604
Drug: GSK2849466
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
Trial: NCT01696604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules will be available.
Trial: NCT00367783
Drug: CP-741,952
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04270760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 5
Trial: NCT04090801
Drug: Topical minoxidil 5% in 90% ethanol and 5% propylene glycol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04090801
Drug: Topical minoxidil 5% in pure ethanol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
Trial: NCT01223742
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice per day
Trial: NCT00591318
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
Trial: NCT00647270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe. See arm for more detail
Trial: NCT02523144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored placebo syrup
Trial: NCT02152280
Drug: Danhong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
Trial: NCT02152280
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
Trial: NCT00131053
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00131053
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00131053
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00131053
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00131053
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00238108
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Trial: NCT00238108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04341428
Drug: DWP14012 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
Trial: NCT04341428
Drug: DWP14012 20 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
Trial: NCT00835211
Drug: DDAVP® 0.2 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 0.2 mg, single-dose fasting
Trial: NCT03219320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo capsules.
Trial: NCT02807675
Drug: CVT-301, LIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
Trial: NCT03879759
Drug: NAC 2400mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400mg/day 2 x 600mg b.d
Trial: NCT03879759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 matched placebo tablets/day
Trial: NCT01110642
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical lovastatin applied to red, rashy areas two times daily for 12 months
Trial: NCT03815318
Drug: Recombinant Human Coagulation FVIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Trial: NCT03425253
Drug: BELKYRA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
Trial: NCT04357223
Drug: extract from Angelica archangelica leaf
RxNorm normalized name: Angelica archangelica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
Trial: NCT04357223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01590758
Drug: Topical placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of treatment
Trial: NCT00178113
Drug: - Certagen (multivitamins with minerals)
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004005
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004005
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00750152
Drug: NAFT-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream application up to 4 weeks
Trial: NCT00750152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream applied for up to 4 weeks
Trial: NCT02238184
Drug: Atrovent®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238184
Drug: Ventilat®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00602927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
Trial: NCT04029766
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00511329
Drug: somatropin [rDNA origin] for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
Trial: NCT03229694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered orally at two hour before surgery and six hours after surgery.
Trial: NCT04267900
Drug: 99mTc-HPArk2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
Trial: NCT02087007
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
Trial: NCT02184052
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 mg or 15 mg
Trial: NCT02215018
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215018
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00095147
Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
Trial: NCT00095147
Drug: Placebo (PLA) + MTX, DB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
Trial: NCT00095147
Drug: PLA + MTX switched to ABA+ MTX, DB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
Trial: NCT00095147
Drug: ABA, open-label (OL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
Trial: NCT04097951
Drug: Combinations
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast and Bepotastine Combination
Trial: NCT00181597
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Taken orally with trilostane.
Trial: NCT00726401
Drug: COLD-fX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg BID for 4 weeks
Trial: NCT00726401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg BID for 4 weeks
Trial: NCT01256086
Drug: Formatris 24µg
RxNorm normalized name: penicillin G 24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
Trial: NCT01256086
Drug: Foradil P 24µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
Trial: NCT02777320
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Trial: NCT00509665
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
Trial: NCT01256086
Drug: Foradil P 12µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
Trial: NCT02774902
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablets
Trial: NCT01226823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Trial: NCT03927378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
Trial: NCT04341727
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antibiotic